Catalym Gmbh

This study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than placebo in people with newly diagnosed metastatic non-squamous non-small cell lung cancer. About 107 adults who have not had prior treatment f…

This study tests a new drug called visugromab combined with nivolumab and/or docetaxel in people with advanced non-squamous lung cancer that has worsened after initial treatment. About 131 participants will receive different combinations to see if the new mix shrinks tumors bette…

This study tests whether adding visugromab to standard drugs (nivolumab and lenvatinib) can help people with advanced liver cancer that has stopped responding to initial treatment. About 104 adults with liver cancer that cannot be removed by surgery or has spread will receive eit…

This study tests a new drug called visugromab in people with advanced cancer who are losing weight unintentionally (cachexia). The goal is to see if the drug helps patients gain weight, improve appetite, and move better. About 518 participants will receive either visugromab or a …